Isomorphic Labs raises €540.0M Series A round
31 March 2025· London, United Kingdom· health, biotechnology, ai, machine_learning, pure_software, b2b, drug_discovery
The funding will be used to accelerate the development of Isomorphic Labs' next-generation AI drug design engine, advance its own programs into clinical development, scale its team, and progress its drug candidate pipeline.
Investors
LeadThrive Capital
Also participating
GVAlphabet
About Isomorphic Labs
Stage
Series A
Headquarters
London, United Kingdom
Founded
2021
Team Size
201–500
Sectors
healthbiotechnologyaimachine_learningpure_softwareb2bdrug_discovery